La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

QuidelOrtho Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Brian Blaser

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Aug 09

QuidelOrtho: Attractive Valuation Despite Weak Performance

Apr 13

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Apr 08

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

Feb 15

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 13

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Feb 18

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

Nov 25

QuidelOrtho forecasts strong Q3 revenue above estimates, shares rise ~6% after hours

Oct 12

QuidelOrtho: Fundamentals Remain, Upbeat Financials

Sep 14

Improved Earnings Required Before QuidelOrtho Corporation (NASDAQ:QDEL) Shares Find Their Feet

Sep 03

QuidelOrtho announces $300M share repurchase authorization

Aug 17

Robust Earnings May Not Tell The Whole Story For QuidelOrtho (NASDAQ:QDEL)

Aug 13

Quidel Non-GAAP EPS of $2.34 misses by $0.51, revenue of $613.4M misses by $27.21M

Aug 04

QuidelOrtho: Continuing Its Upward Ascent

Jul 08

Calculating The Fair Value Of QuidelOrtho Corporation (NASDAQ:QDEL)

Jun 01

AMMINISTRATORE DELEGATO

Brian Blaser (59 yo)

less than a year

Mandato

Mr. Brian J. Blaser serves as CEO & President at QuidelOrtho Corporation since May 06, 2024 & serves as it's Director since May 15, 2024. He served as an Independent Director at Quanterix Corporation since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Busky	Chief Financial Officer	2.3yrs	US$2.94m	0.018% $ 536.4k
Robert Bujarski	Executive VP & COO	3.9yrs	US$3.41m	0.066% $ 2.0m
Werner Kroll	Senior Vice President of Research & Development	10.3yrs	US$2.03m	0.054% $ 1.6m
Michael Iskra	Executive VP & Chief Commercial Officer	less than a year	US$3.32m	0.025% $ 748.0k
Brian Blaser	President	less than a year	Nessun dato	Nessun dato
Juliet Cunningham	Vice President of Investor Relations	less than a year	Nessun dato	Nessun dato
Michelle Hodges	Senior VP	3.7yrs	US$3.55m	0.020% $ 616.2k
William Ferenczy	Point of Care Business Unit Leader	no data	Nessun dato	Nessun dato
Tamara Ranalli	Molecular Diagnostics Business Unit Leader	no data	Nessun dato	Nessun dato

2.3yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di QDEL è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Brian Blaser	President	less than a year	Nessun dato	Nessun dato
Ann Rhoads	Independent Director	4yrs	US$314.47k	0.012% $ 365.4k
Kenneth Widder	Independent Director	9.8yrs	US$320.47k	0.042% $ 1.3m
Kenneth Buechler	Independent Non-Executive Chairman	16.8yrs	US$411.50k	0.13% $ 3.9m
Edward Michael	Independent Director	5.7yrs	US$326.94k	0.023% $ 705.7k
Mary Polan	Independent Director	31.5yrs	US$300.95k	0.035% $ 1.1m
Evelyn Dilsaver	Independent Director	2.3yrs	US$286.95k	0.0077% $ 234.2k
Matthew Strobeck	Independent Director	6.3yrs	US$280.00k	0.044% $ 1.3m
Robert Schmidt	Independent Director	2.3yrs	US$70.00k	Nessun dato
Joseph Wilkins	Independent Director	3.5yrs	US$280.00k	0.0098% $ 295.6k
James Prutow	Independent Director	less than a year	US$110.83k	0.0023% $ 68.3k

4.0yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di QDEL sono considerati esperti (durata media dell'incarico 4 anni).

QuidelOrtho Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

President exercised options and sold US$509k worth of stock

QuidelOrtho Corporation Announces Board Changes

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

Independent Non-Executive Chairman exercised options and sold US$538k worth of stock

Recent updates

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400

QuidelOrtho Corporation to Report Q2, 2024 Results on Jul 31, 2024

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Announces CEO Changes

New major risk - Revenue and earnings growth

QuidelOrtho Corporation to Report Q1, 2024 Results on May 08, 2024

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

QuidelOrtho: Attractive Valuation Despite Weak Performance

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 89%

Price target decreased by 7.0% to US$56.40

QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test

Consensus EPS estimates fall by 602%

QuidelOrtho Corporation Announces CEO Changes

Consensus EPS estimates have been downgraded.

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues miss analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

President exercised options and sold US$509k worth of stock

QuidelOrtho Corporation to Report Q4, 2023 Results on Feb 13, 2024

QuidelOrtho Corporation Provides Revenue Guidance for the Year 2023

QuidelOrtho Corporation Receives 510(K) Clearance for Savanna(R) Multiplex Molecular Platform and Savanna(R) HSV 1+2/VZV PCR Assay

Price target decreased by 7.8% to US$101

QuidelOrtho Corporation Announces Board Changes

Price target decreased by 9.5% to US$110

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Year 2023

QuidelOrtho Corporation to Report Q3, 2023 Results on Nov 01, 2023

QuidelOrtho Corporation Receives CLIA Waiver for Sofia 2 SARS Antigen+ FIA

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

Consensus EPS estimates fall by 31%

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Independent Non-Executive Chairman exercised options and sold US$538k worth of stock

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

President exercised options and sold US$393k worth of stock

QuidelOrtho Corporation Provides Financial Guidance for the Fiscal Year 2023

President exercised options and sold US$341k worth of stock

Consensus forecasts updated

QuidelOrtho Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended January 1, 2023

QuidelOrtho Corporation Announces Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction

Investor sentiment deteriorated over the past week

QuidelOrtho Corporation Announces Executive Changes

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

General Counsel exercised options and sold US$173k worth of stock

High number of new directors

General Counsel exercised options and sold US$173k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President & COO exercised options and sold US$16k worth of stock

Investor sentiment improved over the past week

QuidelOrtho Corporation to Report Q3, 2022 Results on Nov 02, 2022

QuidelOrtho forecasts strong Q3 revenue above estimates, shares rise ~6% after hours

Price target decreased to US$126

President & COO exercised options and sold US$14k worth of stock

QuidelOrtho: Fundamentals Remain, Upbeat Financials

Improved Earnings Required Before QuidelOrtho Corporation (NASDAQ:QDEL) Shares Find Their Feet

QuidelOrtho Corporation (NasdaqGS:QDEL) announces an Equity Buyback for $300 million worth of its shares.

QuidelOrtho announces $300M share repurchase authorization

Robust Earnings May Not Tell The Whole Story For QuidelOrtho (NASDAQ:QDEL)